cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.12592823
title: Additional file 1 of Changes in retinal layer thickness with maturation in the dog: an in vivo spectral domain - optical coherence tomography imaging study

description: Additional file 1 Table S1A. Raw retinal values layer thicknesses (in μm) for each age at 4 optic nerve distance from the optic disk rim. Table S1B. Percentage of retinal layer thicknesses changes relative to the value at 4 weeks of age (raw values in Table S1A). Table S2A. Correlation r values between a given retinal layer thicknesses and retinal region with age. Table S2B.P-values for correlation r values corresponding to a given retinal layer thickness change and retinal region with age and area (corresponding to r value in Table S2A). P-values for a given correlation coefficient are calculated via the F-test, which tests the goodness of fit of the modeled regression by comparing it to a flat line of the mean of the data. Table S3A. Raw retinal values layer thicknesses (in μm) for each age at 1 mm to 7 mm distance from the optic disk rim. Table S3B. Percentage of retinal layer thicknesses changes relative to the value at 1 mm from the optic rim of age (raw values in Table S3A). Table S4A. Correlation r values between a given retinal layer thicknesses, retinal region and eccentricity from the optic disk rim. Table S4B. P-values for correlation r values corresponding to a given retinal layer thickness change, retinal region and eccentricity from the optic disk rim (corresponding to r value in Table S4A). P-values for a given correlation coefficient are calculated via the F-test, which tests the goodness of fit of the modeled regression by comparing it to a flat line of the mean of the data.
DOI: 10.6084/m9.figshare.12592823.v1
title: Additional file 1 of Changes in retinal layer thickness with maturation in the dog: an in vivo spectral domain - optical coherence tomography imaging study

description: Additional file 1 Table S1A. Raw retinal values layer thicknesses (in μm) for each age at 4 optic nerve distance from the optic disk rim. Table S1B. Percentage of retinal layer thicknesses changes relative to the value at 4 weeks of age (raw values in Table S1A). Table S2A. Correlation r values between a given retinal layer thicknesses and retinal region with age. Table S2B.P-values for correlation r values corresponding to a given retinal layer thickness change and retinal region with age and area (corresponding to r value in Table S2A). P-values for a given correlation coefficient are calculated via the F-test, which tests the goodness of fit of the modeled regression by comparing it to a flat line of the mean of the data. Table S3A. Raw retinal values layer thicknesses (in μm) for each age at 1 mm to 7 mm distance from the optic disk rim. Table S3B. Percentage of retinal layer thicknesses changes relative to the value at 1 mm from the optic rim of age (raw values in Table S3A). Table S4A. Correlation r values between a given retinal layer thicknesses, retinal region and eccentricity from the optic disk rim. Table S4B. P-values for correlation r values corresponding to a given retinal layer thickness change, retinal region and eccentricity from the optic disk rim (corresponding to r value in Table S4A). P-values for a given correlation coefficient are calculated via the F-test, which tests the goodness of fit of the modeled regression by comparing it to a flat line of the mean of the data.
DOI: 10.6084/m9.figshare.12592715
title: Additional file 1 of Identification and characterisation of endogenous Avian Leukosis Virus subgroup E (ALVE) insertions in chicken whole genome sequencing data

description: Additional file 1: AF1. Presence/Absence matrix for all identified ALVEs. This file gives the location, names, previous names and any gene or repeat element overlaps for each of the identified ALVEs as well as their presence (1) or absence (0) within each analysed dataset. Dataset names are given as the codes listed in Table S1.
DOI: 10.6084/m9.figshare.12592718
title: Additional file 2 of Identification and characterisation of endogenous Avian Leukosis Virus subgroup E (ALVE) insertions in chicken whole genome sequencing data

description: Additional file 2: AF2. Hy-Line ALVE sequences. This file contains all fifteen successfully sequenced ALVEs from the eight Hy-Line elite layer lines. FASTA headers include sequence genomic orientation, observed length and new GenBank accession numbers where applicable.
DOI: 10.6084/m9.figshare.12592715.v1
title: Additional file 1 of Identification and characterisation of endogenous Avian Leukosis Virus subgroup E (ALVE) insertions in chicken whole genome sequencing data

description: Additional file 1: AF1. Presence/Absence matrix for all identified ALVEs. This file gives the location, names, previous names and any gene or repeat element overlaps for each of the identified ALVEs as well as their presence (1) or absence (0) within each analysed dataset. Dataset names are given as the codes listed in Table S1.
DOI: 10.6084/m9.figshare.12592718.v1
title: Additional file 2 of Identification and characterisation of endogenous Avian Leukosis Virus subgroup E (ALVE) insertions in chicken whole genome sequencing data

description: Additional file 2: AF2. Hy-Line ALVE sequences. This file contains all fifteen successfully sequenced ALVEs from the eight Hy-Line elite layer lines. FASTA headers include sequence genomic orientation, observed length and new GenBank accession numbers where applicable.
DOI: 10.6084/m9.figshare.12592685
title: Additional file 14 of Nutrient solutions for Arabidopsis thaliana: a study on nutrient solution composition in hydroponics systems

description: Additional file 14. R-script used to estimate the nutrient solution EC.
DOI: 10.6084/m9.figshare.12592685.v1
title: Additional file 14 of Nutrient solutions for Arabidopsis thaliana: a study on nutrient solution composition in hydroponics systems

description: Additional file 14. R-script used to estimate the nutrient solution EC.
DOI: 10.6084/m9.figshare.12592631
title: Additional file 1 of Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis

description: Additional file 1: Supplementary Table 1. List of Differentially Expressed Genes. A total of 199 genes were differentially expressed in MSC-like cell-derived ECs from IPF versus non-IPF patients, with 80 genes upregulated and 119 genes downregulated in IPF-ECs. Abbreviations used: CPM, counts per million (reads mapped); EC, epithelial cell; FC, fold change; FDR, false discovery rate; IPF, idiopathic pulmonary fibrosis; MSC, mesenchymal stem cell.
DOI: 10.6084/m9.figshare.12592631.v1
title: Additional file 1 of Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis

description: Additional file 1: Supplementary Table 1. List of Differentially Expressed Genes. A total of 199 genes were differentially expressed in MSC-like cell-derived ECs from IPF versus non-IPF patients, with 80 genes upregulated and 119 genes downregulated in IPF-ECs. Abbreviations used: CPM, counts per million (reads mapped); EC, epithelial cell; FC, fold change; FDR, false discovery rate; IPF, idiopathic pulmonary fibrosis; MSC, mesenchymal stem cell.
DOI: 10.6084/m9.figshare.12592628
title: Additional file 1 of A meta-review of literature reviews assessing the capacity of patients with severe mental disorders to make decisions about their healthcare

description: Additional file 1. Meta- review search strategy.
DOI: 10.6084/m9.figshare.12592628.v1
title: Additional file 1 of A meta-review of literature reviews assessing the capacity of patients with severe mental disorders to make decisions about their healthcare

description: Additional file 1. Meta- review search strategy.
DOI: 10.6084/m9.figshare.12592616
title: Additional file 7 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 7. Logistic regression on factors associated with DAA treatment among patients receiving OAT in 2017. OAT = opioid agonist therapy. Sources: The Swedish Prescribed Drug Register (SPDR) and the Norwegian Prescription Database (NorPD). *Methadone, levomethadone, buprenorphine and buprenorphine-naloxone
DOI: 10.6084/m9.figshare.12592613
title: Additional file 6 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 6. Annual and cumulative DAA and HCV treatment among patients receiving OAT from 2014 to 2017. OAT = opioid agonist therapy, DAA = direct-acting antiviral agent, OR = odds ratio, aOR = adjusted odds ratio, CI = confidence interval. Source: The Norwegian Prescription Database (NorPD) and The Swedish Prescribed Drug Register (SPDR). *N05BA01, N05BA04, N05BA06, N05BA12, N05CD02, N05CD03, N05CD08, N03AE01. **N05CF01 and N05CF02. ***N03AA, N03AB, N03AF, N03AG, N03AX. ****N06AA, N06AB, N06AF, N06AG, N06AX. *****N05AA, N05AB, N05AC, N05AD, N05AE, N05AF, N05AG, N05AH, N05AL, N05AN, N05AX. For ATC codes see additional file 4
DOI: 10.6084/m9.figshare.12592616.v1
title: Additional file 7 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 7. Logistic regression on factors associated with DAA treatment among patients receiving OAT in 2017. OAT = opioid agonist therapy. Sources: The Swedish Prescribed Drug Register (SPDR) and the Norwegian Prescription Database (NorPD). *Methadone, levomethadone, buprenorphine and buprenorphine-naloxone
DOI: 10.6084/m9.figshare.12592607
title: Additional file 4 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 4. Anatomical Therapeutic Chemical Classification and defined daily dose for OAT medications. OAT = opioid agonist therapy; SD = standard deviation; Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). *Last registered OAT medication each calendar year
DOI: 10.6084/m9.figshare.12592610
title: Additional file 5 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 5. Basic characteristics of patients receiving OAT from 2014 to 2017 in Sweden and Norway. OAT = opioid agonist therapy, HCV = hepatitis C virus infection, DAA = direct-acting antiviral agent, CI = confidence interval. Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). *Exluding Ribavirin (J05AP01)
DOI: 10.6084/m9.figshare.12592613.v1
title: Additional file 6 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 6. Annual and cumulative DAA and HCV treatment among patients receiving OAT from 2014 to 2017. OAT = opioid agonist therapy, DAA = direct-acting antiviral agent, OR = odds ratio, aOR = adjusted odds ratio, CI = confidence interval. Source: The Norwegian Prescription Database (NorPD) and The Swedish Prescribed Drug Register (SPDR). *N05BA01, N05BA04, N05BA06, N05BA12, N05CD02, N05CD03, N05CD08, N03AE01. **N05CF01 and N05CF02. ***N03AA, N03AB, N03AF, N03AG, N03AX. ****N06AA, N06AB, N06AF, N06AG, N06AX. *****N05AA, N05AB, N05AC, N05AD, N05AE, N05AF, N05AG, N05AH, N05AL, N05AN, N05AX. For ATC codes see additional file 4
DOI: 10.6084/m9.figshare.12592601
title: Additional file 2 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 2. Flowchart of study populations in Norway and Sweden from 2014 to 2017. According to World Health Organization Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index. OAT = opioid agonist therapy, DDD = defined daily dose. The DDDs are the assumed average maintenance dose per day for a drug used for its main indication. *Therapeutic subgroup, chemical subgroup, or chemical substance. **Including clonazepam. ***Excluding clonazepam
DOI: 10.6084/m9.figshare.12592610.v1
title: Additional file 5 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 5. Basic characteristics of patients receiving OAT from 2014 to 2017 in Sweden and Norway. OAT = opioid agonist therapy, HCV = hepatitis C virus infection, DAA = direct-acting antiviral agent, CI = confidence interval. Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). *Exluding Ribavirin (J05AP01)
DOI: 10.6084/m9.figshare.12592601.v1
title: Additional file 2 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 2. Flowchart of study populations in Norway and Sweden from 2014 to 2017. According to World Health Organization Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index. OAT = opioid agonist therapy, DDD = defined daily dose. The DDDs are the assumed average maintenance dose per day for a drug used for its main indication. *Therapeutic subgroup, chemical subgroup, or chemical substance. **Including clonazepam. ***Excluding clonazepam
DOI: 10.6084/m9.figshare.12592607.v1
title: Additional file 4 of Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

description: Additional file 4. Anatomical Therapeutic Chemical Classification and defined daily dose for OAT medications. OAT = opioid agonist therapy; SD = standard deviation; Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). *Last registered OAT medication each calendar year
DOI: 10.6084/m9.figshare.12592544
title: Species-specific magnetosome biomineralization as a foundation for environmental interpretation of ancient magnetofossils

description: Magnetosome morphology dataset, including crystal length, width and axial ratio, of 20 uncultured magnetotactic cocci strains identified by FISH-SEM method on single cell level. And magnetosome morphology features (magnetosome number, chain configuration, average crystal width and axial ratio) for NMDS analysis.
DOI: 10.6084/m9.figshare.12592538
title: Supplementary Material for: Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System

description: <b><i>Background:</i></b> Hidradenitis suppurativa (HS) is a neglected chronic inflammatory disease with long delay in diagnosis. Besides pain, purulent discharge, and destruction of skin architecture, HS patients experience metabolic, musculoskeletal, and psychological disorders. <b><i>Objectives:</i></b> To determine the delay in HS diagnosis and its consequences for patients and the healthcare system. <b><i>Methods:</i></b> This was a prospective, multicenter, epidemiologic, non-interventional cross-sectional trial carried out in Germany and based on self-reported questionnaires and medical examinations performed by dermatologists. In total, data of 394 adult HS patients were evaluated. <b><i>Results:</i></b> The average duration from manifestation of first symptoms until HS diagnosis was 10.0 ± 9.6 (mean ± SD) years. During this time, HS patients consulted on average more than 3 different physicians – most frequently general practitioners, dermatologists, surgeons, gynecologists – and faced more than 3 misdiagnoses. Diagnosis delay was longer in younger and non-smoking patients. In most cases, HS was correctly diagnosed by dermatologists. The longer the delay of diagnosis, the greater the disease severity at diagnosis. Delayed HS diagnosis was also associated with an increased number of surgically treated sites, concomitant diseases, and days of work missed. <b><i>Conclusion:</i></b> This study demonstrates an enormous delay in the diagnosis of HS, which results in more severe disease. It also shows for the first time that a delay in diagnosis of a chronic inflammatory disease leads to a higher number of concomitant systemic disorders. In addition to the impaired health status, delayed diagnosis of HS was associated with impairment of the professional life of affected people.
DOI: 10.6084/m9.figshare.12592544.v1
title: Species-specific magnetosome biomineralization as a foundation for environmental interpretation of ancient magnetofossils

description: Magnetosome morphology dataset, including crystal length, width and axial ratio, of 20 uncultured magnetotactic cocci strains identified by FISH-SEM method on single cell level. And magnetosome morphology features (magnetosome number, chain configuration, average crystal width and axial ratio) for NMDS analysis.
DOI: 10.6084/m9.figshare.12592532
title: DeepBrainNetModel.h5

description: Model trained for brain age taken from here https://github.com/vishnubashyam/DeepBrainNet<br><br>
DOI: 10.6084/m9.figshare.12592538.v1
title: Supplementary Material for: Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System

description: <b><i>Background:</i></b> Hidradenitis suppurativa (HS) is a neglected chronic inflammatory disease with long delay in diagnosis. Besides pain, purulent discharge, and destruction of skin architecture, HS patients experience metabolic, musculoskeletal, and psychological disorders. <b><i>Objectives:</i></b> To determine the delay in HS diagnosis and its consequences for patients and the healthcare system. <b><i>Methods:</i></b> This was a prospective, multicenter, epidemiologic, non-interventional cross-sectional trial carried out in Germany and based on self-reported questionnaires and medical examinations performed by dermatologists. In total, data of 394 adult HS patients were evaluated. <b><i>Results:</i></b> The average duration from manifestation of first symptoms until HS diagnosis was 10.0 ± 9.6 (mean ± SD) years. During this time, HS patients consulted on average more than 3 different physicians – most frequently general practitioners, dermatologists, surgeons, gynecologists – and faced more than 3 misdiagnoses. Diagnosis delay was longer in younger and non-smoking patients. In most cases, HS was correctly diagnosed by dermatologists. The longer the delay of diagnosis, the greater the disease severity at diagnosis. Delayed HS diagnosis was also associated with an increased number of surgically treated sites, concomitant diseases, and days of work missed. <b><i>Conclusion:</i></b> This study demonstrates an enormous delay in the diagnosis of HS, which results in more severe disease. It also shows for the first time that a delay in diagnosis of a chronic inflammatory disease leads to a higher number of concomitant systemic disorders. In addition to the impaired health status, delayed diagnosis of HS was associated with impairment of the professional life of affected people.
DOI: 10.6084/m9.figshare.12592520
title: JVASP-2274 to JVASP-4409

description: JARVIS-DFT input/output files
DOI: 10.6084/m9.figshare.12592523
title: JVASP-4412 to JVASP-8007

description: JARVIS-DFT input/output files
DOI: 10.6084/m9.figshare.12592529
title: CCT

description: GWAS summary statistics on corneal thickness
DOI: 10.6084/m9.figshare.12592529.v1
title: CCT

description: GWAS summary statistics on corneal thickness
DOI: 10.6084/m9.figshare.12592532.v1
title: DeepBrainNetModel.h5

description: Model trained for brain age taken from here https://github.com/vishnubashyam/DeepBrainNet<br><br>
DOI: 10.6084/m9.figshare.12592496
title: JVASP-5 to JVASP-2268

description: JARVIS-DFT input/output files
DOI: 10.6084/m9.figshare.12592466
title: Data for "Picometre-precision analysis of scanning transmission electron microscopy images of platinum nanocatalysts"

description: Data for Yankovich, A. B., Berkels, B., Dahmen, W., Binev, P., Sanchez, S. I., Bradley, S. a., Li, A., Szlufarska, I. & Voyles, P. M. Picometre-precision analysis of scanning transmission electron microscopy images of platinum nanocatalysts. Nat. Commun. 5, 4155 (2014). DOI: 10.1038/ncomms5155
DOI: 10.6084/m9.figshare.12592478
title: Data for "Non-rigid registration and non-local principle component analysis to improve electron microscopy spectrum images"

description: Data for Yankovich, A. B., Zhang, C., Oh, A., Slater, T. J. A., Azough, F., Freer, R., Haigh, S. J., Willett, R. & Voyles, P. M. Non-rigid registration and non-local principle component analysis to improve electron microscopy spectrum images. Nanotechnology 27, 364001 (2016). DOI: 10.1088/0957-4484/27/36/364001
DOI: 10.6084/m9.figshare.12592457
title: Data for "Poisson noise removal from high-resolution STEM images based on periodic block matching"

description: Data for Mevenkamp, N., Binev, P., Dahmen, W., Voyles, P. M., Yankovich, A. B. & Berkels, B. Poisson noise removal from high-resolution STEM images based on periodic block matching. Adv. Struct. Chem. Imaging 1, 3 (2015). DOI: 10.1186/s40679-015-0004-8
DOI: 10.6084/m9.figshare.12592466.v1
title: Data for "Picometre-precision analysis of scanning transmission electron microscopy images of platinum nanocatalysts"

description: Data for Yankovich, A. B., Berkels, B., Dahmen, W., Binev, P., Sanchez, S. I., Bradley, S. a., Li, A., Szlufarska, I. & Voyles, P. M. Picometre-precision analysis of scanning transmission electron microscopy images of platinum nanocatalysts. Nat. Commun. 5, 4155 (2014). DOI: 10.1038/ncomms5155
DOI: 10.6084/m9.figshare.12592457.v1
title: Data for "Poisson noise removal from high-resolution STEM images based on periodic block matching"

description: Data for Mevenkamp, N., Binev, P., Dahmen, W., Voyles, P. M., Yankovich, A. B. & Berkels, B. Poisson noise removal from high-resolution STEM images based on periodic block matching. Adv. Struct. Chem. Imaging 1, 3 (2015). DOI: 10.1186/s40679-015-0004-8
DOI: 10.6084/m9.figshare.12592361
title: Input data - radar and gauge data of a 15 min and a 30 min events - for simulating surface precipitation fields using random mixing

description: The Python script "dataPrepare.py" describes, analyzes and displays the data. The Python script "marginal.py" manages the marginal conversions (standard normal, precipitation and quantiles).
DOI: 10.6084/m9.figshare.12592364
title: JVASP-86545 to JVASP-88384

description: JARVIS-DFT input/output files
DOI: 10.6084/m9.figshare.12592331
title: Tiny example data for kraken2 human read-removal example

description: example data for kraken2 human read-removal from here: https://hackmd.io/@astrobiomike/kraken2-human-read-removal
DOI: 10.6084/m9.figshare.12592331.v1
title: Tiny example data for kraken2 human read-removal example

description: example data for kraken2 human read-removal from here: https://hackmd.io/@astrobiomike/kraken2-human-read-removal
DOI: 10.6084/m9.figshare.12592250
title: JVASP-85700 to JVASP-86544

description: JARVIS-DFT input/output files
DOI: 10.6084/m9.figshare.12592244
title: kraken2_human_db

description: created on 30-June-2020 as detailed here: https://hackmd.io/@astrobiomike/kraken2-human-read-removal
DOI: 10.6084/m9.figshare.12592244.v1
title: kraken2_human_db

description: created on 30-June-2020 as detailed here: https://hackmd.io/@astrobiomike/kraken2-human-read-removal